Randomized, double-blind trial of 220mg zinc sulfate twice daily in the treatment of rosacea

Joel T.M. Bamford, Charles E. Gessert, Irina V. Haller, Kim Kruger, Brian P. Johnson

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

A 2006 article published in the International Journal of Dermatology reported that oral zinc sulfate 100mg three times daily was associated with improvement in the severity of facial rosacea (Sharquie et al. 2006; 45: 857-861). The current study was undertaken to further assess the role of zinc in the management of rosacea. This was a randomized, double-blind trial of 220mg of zinc sulfate twice daily for 90days in patients with moderately severe facial rosacea at baseline. Subjects were recruited in the Upper Midwest USA between August 2006 and April 2008, and followed until July 2008. Forty-four subjects completed the trial (22 in each arm). Rosacea improved in both groups. There were no differences in magnitude of improvement based on rosacea severity scores between subjects receiving zinc sulfate and subjects receiving placebo (P=0.284). Serum zinc levels were higher in subjects receiving zinc (P<0.001). Oral zinc sulfate was not associated with greater improvement in rosacea severity compared with placebo in this study. Additional studies are needed to determine what role oral zinc may have in the management of rosacea.

Original languageEnglish (US)
Pages (from-to)459-462
Number of pages4
JournalInternational Journal of Dermatology
Volume51
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint Dive into the research topics of 'Randomized, double-blind trial of 220mg zinc sulfate twice daily in the treatment of rosacea'. Together they form a unique fingerprint.

Cite this